| Risk of venous thromboembolism in patients with COVID‐19: a systematic review and meta‐analysis S Nopp, F Moik, B Jilma, I Pabinger, C Ay Research and practice in thrombosis and haemostasis 4 (7), 1178-1191, 2020 | 490 | 2020 |
| Venous thromboembolism in cancer patients: a population-based cohort study FI Mulder, E Horvàth-Puhó, N van Es, HWM Van Laarhoven, L Pedersen, ... Blood, The Journal of the American Society of Hematology 137 (14), 1959-1969, 2021 | 395 | 2021 |
| Cancer-associated venous thromboembolism AA Khorana, N Mackman, A Falanga, I Pabinger, S Noble, W Ageno, ... Nature reviews Disease primers 8 (1), 11, 2022 | 203 | 2022 |
| Outpatient pulmonary rehabilitation in patients with long COVID improves exercise capacity, functional status, dyspnea, fatigue, and quality of life S Nopp, F Moik, FA Klok, D Gattinger, M Petrovic, K Vonbank, ... Respiration 101 (6), 593-601, 2022 | 181 | 2022 |
| Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy F Moik, WSE Chan, S Wiedemann, C Hoeller, F Tuchmann, MB Aretin, ... Blood, The Journal of the American Society of Hematology 137 (12), 1669-1678, 2021 | 167 | 2021 |
| Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized … F Moik, F Posch, C Zielinski, I Pabinger, C Ay Research and practice in thrombosis and haemostasis 4 (4), 550-561, 2020 | 88 | 2020 |
| Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future F Moik, C Ay, I Pabinger Thrombosis research 191, S3-S11, 2020 | 46 | 2020 |
| SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic T Fuereder, AS Berghoff, G Heller, H Haslacher, T Perkmann, R Strassl, ... ESMO open 5 (5), e000889, 2020 | 43 | 2020 |
| How I treat cancer-associated thrombosis F Moik, I Pabinger, C Ay ESMO open 4, e000610, 2019 | 42 | 2019 |
| Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer Y Hisada, KB Garratt, A Maqsood, SP Grover, T Kawano, BC Cooley, ... Blood Advances 5 (2), 487-495, 2021 | 41 | 2021 |
| Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis JM Riedl, F Posch, L Horvath, A Gantschnigg, F Renneberg, ... European Journal of Cancer 151, 3-13, 2021 | 40 | 2021 |
| Outpatient pulmonary rehabilitation in patients with persisting symptoms after pulmonary embolism S Nopp, FA Klok, F Moik, M Petrovic, I Derka, C Ay, RH Zwick Journal of clinical medicine 9 (6), 1811, 2020 | 33 | 2020 |
| Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting JM Riedl, F Posch, F Moik, A Bezan, J Szkandera, MA Smolle, ... Oncotarget 8 (56), 96048, 2017 | 33 | 2017 |
| Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer F Moik, F Posch, E Grilz, W Scheithauer, I Pabinger, G Prager, C Ay Thrombosis research 187, 9-17, 2020 | 32 | 2020 |
| Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review F Moik, M Colling, I Mahé, L Jara‐Palomares, I Pabinger, C Ay Journal of Thrombosis and Haemostasis 20 (3), 619-634, 2022 | 30 | 2022 |
| Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer F Moik, S Zöchbauer-Müller, F Posch, I Pabinger, C Ay Cancers 12 (6), 1619, 2020 | 30 | 2020 |
| ABO blood group type and risk of venous thromboembolism in patients with cancer C Englisch, F Moik, S Nopp, M Raderer, I Pabinger, C Ay Blood Advances 6 (24), 6274-6281, 2022 | 28 | 2022 |
| Hemostatic biomarkers and venous thromboembolism are associated with mortality and response to chemotherapy in patients with pancreatic cancer F Moik, G Prager, J Thaler, F Posch, S Wiedemann, T Schramm, ... Arteriosclerosis, thrombosis, and vascular biology 41 (11), 2837-2847, 2021 | 24 | 2021 |
| Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis F Moik, JM Riedl, T Winder, A Terbuch, CH Rossmann, J Szkandera, ... Scientific Reports 9 (1), 5548, 2019 | 22 | 2019 |
| Alterations of the platelet proteome in lung cancer: accelerated F13A1 and ER processing as new actors in hypercoagulability H Ercan, LM Mauracher, E Grilz, L Hell, R Hellinger, JA Schmid, F Moik, ... Cancers 13 (9), 2260, 2021 | 21 | 2021 |
